Xiaoli Wang, PhD
About Me
Dr. Wang completed her bachelor, master degrees in China in 1994 and 1998, respectively. She received her Ph.D. in Radiology at Jilin University, China in 2001. Dr. Wang did her post-doctoral training in Pathology/Hematology at Kansai Medical University, Japan. Currently, she is faculty member of Division of Hematology/Medical Oncology, Department of Medicine at Icahn School of Medicine at Mount Sinai. Dr. Wang has been Co-Investigator on NIH-funded research projects within the MPN Research Consortium, Principle Investigator on MPN Research Foundation and industry sponsored preclinical studies. She is conducting research independently and within the MPN Research Consortiums. Her research efforts have been focused on understanding normal and malignant hematopoietic stem cell biology and pre-clinical evaluation of effectiveness of small molecule inhibitors as well as immunotherapeutic approaches in eliminating malignant stem cells of patients with MPNs and patients with MPN-Blast Phase (MPN-BP). Dr. Wang’s research has been published in 27 highly ranked peer-reviewed journals including J Clin Invest and Blood and her expertise has been recognized by multiple collaborators.
Language
English
Position
ASSISTANT PROFESSOR | Medicine, Hematology and Medical Oncology
Research Topics
Cancer, Cell Biology, Cell Transformation, Hematopoiesis, Stem Cells, Translational Research
Education
MD, Jilin Medical College
MS, Norman Bethune University of Medical Sciences
PhD, Jilin University
, Icahn School of Medicine at Mount Sinai
, Kansai Medical University
Awards
MF Challenge Concept Grant
The MPN Research Foundation (MPNRF) and the Leukemia & Lymphoma Society (LLS)
ASH Travel Award 2008
American Society of Hematology
ASH Travel Award 2009
American Society of Hematology
Research
Publications
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device, biotechnology companies, and other outside entities to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their outside financial relationships.
Dr. Wang has not yet completed reporting of Industry relationships.
Mount Sinai’s faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.